Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Japan’s Generic Market Projected to Top 900 Billion Yen in 2017: Fuji Keizai
April 16, 2015
- JCR Successfully Develops Blood-Brain Barrier-Passing Technology; First Application to Be Drug for Hunter Syndrome
April 16, 2015
- NIID, ID Pharma to Collaborate on Research for Therapeutic Vaccines for AIDS
April 16, 2015
- Nesina’s Cardiovascular Profile Acceptable: FDA Advisory Panel
April 16, 2015
- Lixiana Gains Swiss Nod, First Approval in Europe: Daiichi Sankyo
April 16, 2015
- MSD, Astellas to Develop Januvia-Suglat Combination Drug
April 16, 2015
- Hisamitsu Initiates PIII Study of Transdermal Parkinson’s Disease Treatment Ropinirole in Japan
April 16, 2015
- Eisai to Collaborate with Genomics for Drug Discovery
April 14, 2015
- Japan CSO Association Aims to Double No. of Contract Sales Reps to 8,000 by FY2020
April 14, 2015
- ViiV Healthcare Launches HIV Treatment Triumeq Combination Tablets
April 13, 2015
- Japan Vaccine Files NDA for Intradermal Influenza Vaccine
April 13, 2015
- Show Timelines for Vaccine Inclusion in Public Immunization Program: Pfizer Exec
April 10, 2015
- Ethical Drug Sales Down 1.4% in February: Crecon Report
April 10, 2015
- IFN-Free, All Oral Treatment for Hepatitis C Demonstrates Impressive Response Rate
April 10, 2015
- Livalo Shows No Negative Effects on Fasting Blood Glucose Levels, HbA1c: Kowa
April 10, 2015
- Regience Partners with Keio Univ. for Joint Research of Liver Regeneration
April 10, 2015
- Announcement: 8th Annual Marketing Excellence Japan 2015 - Westin Tokyo, May 12-13
April 9, 2015
- Novo Nordisk’s Japan Sales Bounce Back to Hit All-Time High
April 9, 2015
- Hisamitsu Sales Up 4.1% despite Dull Japan Biz, Mohrus Down 8.5%
April 9, 2015
- Eli Lilly Japan Sales Cross 200 Billion Yen in 2014, Top 10 Eyed by 2020
April 9, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…